Far Infrared Treatment for Kidney Diseases - Full Text View

Sponsored by:	GAAD Medical Research Institute Inc.
Information provided by:	GAAD Medical Research Institute Inc.
ClinicalTrials.gov Identifier:	NCT00599391

Purpose

Renal failure or kidney failure is a situation in which the kidneys fail to function adequately. It is divided into acute and chronic forms; either form may be due to a large number of other medical problems.

Condition	Intervention	Phase
Kidney Failure	Radiation: Far Infrared Radiation (5μm to 20μm wavelength)	Phase I

MedlinePlus related topics: Kidney Failure

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study
Official Title:	Phase 1 Study to Examine the Use of Far Infrared Radiation for Renal Failure.

Further study details as provided by GAAD Medical Research Institute Inc.:

Primary Outcome Measures:

Kidney Function Improvement [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Causes of Mortality [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Estimated Enrollment:	10
Study Start Date:	February 2008
Estimated Study Completion Date:	February 2009
Estimated Primary Completion Date:	October 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1 Far Infrared Radiation	Radiation: Far Infrared Radiation (5μm to 20μm wavelength) Far Infrared Radiation for 30 to 40 minutes per session.

Detailed Description:

There are many causes of chronic kidney disease. The most common cause is diabetes mellitus. Acute renal failure is a rapidly progressive loss of renal function, generally characterized by body fluids disturbances and electrolyte derangement.

It is believed that far infrared radiation of the central nervous system, the endocrine system and the kidneys will help in the management of renal failure and a possible cure.

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

People with kidney diseases

Exclusion Criteria:

None

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00599391

Locations

Canada, Ontario
The Centre for Incurable Diseases
Toronto, Ontario, Canada, M4V 1L5

Sponsors and Collaborators

GAAD Medical Research Institute Inc.

Investigators

Study Chair:	Ken Nedd, M.D.	GAAD Medical Research Institute Inc.
Study Director:	Kwasi Donyina, Ph.D.	GAAD Medical Research Institute Inc.

More Information

Responsible Party:	GAAD Medical Research Institute Inc. ( Dr. Kwasi Donyina/Founder and President )
Study ID Numbers:	GAAD-RF-CTP1
Study First Received:	January 11, 2008
Last Updated:	January 2, 2009
ClinicalTrials.gov Identifier:	NCT00599391
Health Authority:	Canada: Health Canada

Keywords provided by GAAD Medical Research Institute Inc.:

KIDNEY FAILURE, ACUTE
KIDNEY FAILURE, CHRONIC
RENAL INSUFFICIENCY

Study placed in the following topic categories:

Renal Insufficiency
Urologic Diseases
Kidney Failure, Chronic

Kidney Failure, Acute
Kidney Diseases
Kidney Failure

ClinicalTrials.gov processed this record on January 14, 2009